Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | SCRI-CARB7H3(s)x19 |
| Trade Name | |
| Synonyms | |
| Drug Descriptions |
SCRI-CARB7H3(s)x19 comprises CD4- and CD8-positive autologous T-lymphocytes engineered to express a chimeric antigen receptor (CAR) targeting CD276 (B7-H3) and CD19, truncated EGFR (EGFRt), and undisclosed costimulatory domains, which potentially induce toxicity in tumor cells expressing CD276 (B7-H3) and CD19 (NCI Drug Dictionary). |
| DrugClasses | CD19 Immune Cell Therapy 74 CD276 Immune Cell Therapy 12 |
| CAS Registry Number | NA |
| NCIT ID | C171318 |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| SCRI-CARB7H3(s)x19 | SCRI-CARB7H3(s)x19 | 0 | 0 |